Background: Recent genome-wide sequencing studies have identified unexpected genetic alterations in cancer. In particular, missense mutations in isocitrate dehydrogenase-1 (IDH1) at arginine 132, mostly substituted into histidine (IDH1-R132H) were observed to frequently occur in glioma patients. Methods: We have purified recombinant IDH1 and IDH1-R132H proteins and monitored their catalytic activities. In parallel experiments, we have attempted to find new selective IDH1-R132H chemical inhibitor(s) from a fragment-based chemical library.
INTRODUCTION
Cancer is an example of common human disease, in which cellular metabolisms are significantly altered, thereby exhibiting a substantially different production of cellular metabolites. 1 More than decades ago, Warburg 2 has observed that proliferating cancer cells preferentially convert the majority of glucose to lactate, but not to the oxidative phosphorylation for glucosedependent adenosine triphosphate production even in oxygenrich conditions, a phenomenon commonly referred to as 'the Warburg effect'. Although no single genetic aberration is common to all cancer types, the metabolic switch into the aerobic glycolysis is universal to nearly all proliferating cancer cells, regardless of their origin. Therefore, this property has been exploited in the clinic for diagnosis of cancer, using 18 F-deoxyglucose positron emission tomography.
Results from recent genome-wide sequencing studies have illustrated that somatic mutations in the isocitrate dehydrogenase-1 (IDH1) commonly exist in the majority of patients with grade II to III primary gliomas and secondary glioblastomas multiforme. 3 Interestingly, IDH1 mutations were confined at a single residue, e.g., arginine 132, which was mostly mutated into histidine (IDH1-R132H). 4 IDH1 is a cytosolic enzyme that catalyzes the oxidative decarboxylation of isocitrate (ICT) into α-ketoglutarate (α-KG) with a concomitant production of reduced nicotinamide adenine dinucleotide phosphate (NADPH). Structural analysis shows that IDH1 arginine residue at 132 is located in the active site of the enzyme and participates in the binding of ICT. 5 In addition, somatic IDH1 mutations were observed to be heterozygous: only a single copy of the homologous genes is mutated. 6 Because the enzymes, mutated in the active site generally exhibit decreased enzymatic activities, IDH1 mutations were thought to cause a loss of function of enzyme. 7 However, it was soon noticed that IDH1-R132H exhibits an additional novel enzyme activity: it converts α-KG into a stereoselective (R)-2-hydroxyglutarate (R-2HG). 8 Subsequent studies have demonstrated that treatment of R-2HG is sufficient to promote reversible leukemogenesis in vitro 9 and glioma patients harboring IDH1 mutations had an increased R-2HG level in the brain, 10 suggesting a possibility that R-2HG might be an oncometabolite. In the present study, we have measured the catalytic activity of recombinant IDH1 and IDH1-R132H enzymes and found out that a heterozygous IDH1-R132H mutation might be required to fulfill the two-step enzymatic conversion of ICT into R-2HG. In addition, we have identified a new selective IDH1-R132H chemical hit molecule from a fragment-based chemical library.
MATERIALS AND METHODS

Preparation of recombinant IDH1 and IDH1-R132H proteins
Human IDH1 cDNA (GenBank Number, AF020038) was purchased from Korea Human Gene Bank (Daejeon, Korea). A site-directed mutagenesis using an overlapping polymerase chain reaction was conducted to create a mutant IDH1 cDNA (IDH1-R132H). Both wild-type and mutant IDH1 cDNAs were subcloned into the pET21 vector and transformed into BL21 cells. Cells were grown in LB media at 37 
Transient transfection and Western blot analysis
293T cells were grown in Dulbecco's Modified Eagle's Medium media supplemented with 10% fetal bovine serum. Seventy percent confluent 293T cells in 100 mm dish were transfected with 3 μg pcDNA3-HA-IDH1 or pcDNA3-HA-IDH1-R132H plasmids with JetPEI reagent (Polyplus Transfection, New York, NY, USA). After 24 hours transfection, 293T cell lysates were collected with 200 μL sodium dodecyl sulfate (SDS) lysis buffer (50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 1% SDS, 1 mM Na3VO4, 1 mM dithiothreitol, 1 mM PMSF) and kept on ice for 30 minutes. After centrifugation at 12,000 rpm for 10 minutes, the protein concentration was measured using a BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). An equal amount of cell lysates were resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (BioRad, Hercules, CA, USA). The membranes were incubated in blocking buffer (5% skim milk in 1 × phosphate buffered saline [PBS]-0.1% Tween-20, [PBST]) for 1 hour and hybridized with the appropriate primary antibodies in 1× PBS, containing 3% bovine serum albumin or 3% skim milk overnight at 4 o C. Primary antibodies used in our study are as follows: H3K9me3 (abcam, Cambridge, UK; ab8898), H3K27me3 (Millipore, Billerica, MA, USA; 07-449), H3K36me3 (abcam; ab9050), H3K79me3 (abcam; ab2621), total H3 (Millipore; 05-928) and HA (Cell Signaling Technology, Danvers, MA, USA; 2367). After washing three times with 1 × PBST for 30 minutes, the membrane was hybridized with horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 hour at room temperature and washed three times with 1 × PBST solution for 30 minutes. The membrane was visualized by using an enhanced chemiluminescence detection system.
RESULTS
Recombinant IDH1-R132H do not convert α-KG into R-2HG
We have prepared recombinant IDH1 and IDH1-R132H enzymes via IPTG induction in Escherichia coli, followed by a nickel-based affinity purification and dialysis. Coomassie blue staining illustrates that both IDH1 and IDH1-R132H proteins are soluble (Fig. 1A) . Because IDH1 requires NADP + as a cofactor, the IDH1 activity converting ICT into α-KG can be indirectly quantified by measuring the amount of resulting NADPH at 340 nm by spectrophotometry (Fig. 1B, upper panel) . Our results show that IDH1 efficiently converts ICT into α-KG through a coupled reduction of NADP + into NADPH, while IDH1-R132H fails to do so (Fig. 1B, lower panel) . As stated earlier, it is known that IDH1-R132H gains a new enzyme activity, e.g., catalysis of α-KG into R-2HG, which can be indirectly assessed by measuring the formation of NADP + from NADPH (Fig. 1C, upper panel) .
However, it is unclear whether this activity also occurs in IDH1. Our result illustrates that both IDH1 and IDH1-R132H can convert α-KG into R-2HG, although the degree of this metabolic conversion by IDH1-R132H was far more efficient, when compared with that by IDH1 (Fig. 1C, lower panel) .
Overexpression of IDH1-R132H strongly elevated the H3K36me3 and H3K79me3 levels in HEK293T cells
Previous studies have demonstrated that R-2HG acts as an antagonist of α-KG to competitively inhibit a number of KGdependent dioxygenases, including the JmjC domain-containing histone demethylases (KDMs) and the TET (ten-eleven translocation) family of DNA hydroxylases. 11 We have transfected pcDNA3 vector, pcDNA3-HA-IDH1 and pcDNA3-HA-IDH1-R132H plasmids into HEK293T cells and measured the resulting global changes of histone H3 trimethylation levels at Lysine 9 (H3K9me3), Lysine 27 (H3K27me), Lysine 36 (H3K36me3) and Lysine 79 (H3K79me3). As a result, we observed that overexpression of IDH1-R132H in 293T cells significantly increased the endogenous levels of H3K36me3 and H3K79me3, but not that of H3K9me3 and H3K27me3 (data not shown), when compared with 293T cells overexpressed with wild-type IDH1 (Fig. 1D) . The exact reason why H3K9me3 and H3K27me3 levels were unaffected by overexpression of IDH1-R132H in our experiment setup is currently unclear. Our results suggest that IDH-R132H might elevate the H3K36me3 and H3K79me3 levels in HEK293T cells, possibly via the production of R-2HG.
Identification of a novel selective IDH1-R132H inhibitor from fragment-based chemical library
In order to find out new selective IDH1-R132H chemical inhibitors, we have screened 500 synthetic chemicals derived from a fragment-based chemical library at the concentration of 5 μM. While several synthetic chemicals exhibited mild inhibitory effects, we observed that a synthetic fragment chemical (No. 398) strongly inhibited the IDH1-R132H activity more than 80% (Fig.  2A) . The chemical was identified to be 2-(3-trifluoromethylphenyl)isothioazol-3(2H)-one and its chemical structure is provided herein (Fig. 2B) . In order to exclude the possibility whether this compound also interferes with the wild-type IDH1 activity, the recombinant IDH1 protein was mixed with 2-(3-trifluoromethylphenyl)isothioazol-3(2H)-one and the resulting enzymatic activity was assessed. As a result, we observed that 2-(3-trifluoromethylphenyl)isothioazol-3(2H)-one does not interfere with the IDH1 activity, demonstrating the selectivity of this compound against IDH1-R132H (Fig. 2C) .
DISCUSSION
As stated earlier, the next-generation sequencing studies have identified that the IDH1 mutations found in glioma patients exhibit a heterozygous, but not homozygous pattern. Our data enable us to speculate the biochemical mechanisms how a heterozygous IDH1-R132H mutation contributes to the formation of R-2HG in vivo: if the IDH1 mutation is homozygous, the generation of R-2HG from ICT would be impossible because IDH1-R132H can't convert ICT into α-KG (Fig. 1B) . This might explains why heterozygous, but not homozygous IDH1 mutations are exclusively found in glioma patients. In addition, we have demonstrated that 2-(3-trifluoromethylphenyl)isothioazol-3(2H)-one inhibits the IDH1-R132H activity without affecting the IDH1 activity ( Fig. 2A and 2C ). In line with our discovery, other investigators have reported selective chemical inhibitors of IDH1-R132H. For example, Rohle et al. 12 have identified a selective R132H-IDH1 inhibitor, e.g., AGI-5198, through a highthroughput screen and demonstrated that AGI-5198 selectively attenuated the growth of glioma xenografts harboring IDH1-R132H, but not IDH1. In addition, Zheng et al. 13 have screened a focused library and identified two derivatives of 5-benzyl-1-hydroxypyridin-2-one as IDH1-R132H and IDH1-R132C specific inhibitors. Moreover, Davis et al. 14 have recently identified ML309 as a selective chemical inhibitor of IDH1-R132H and found that it competitively inhibits the binding of α-KG to the mutant IDH1 enzymes, IDH1-R132H and IDH1-R132C. In the present study, we also provide a new selective chemical inhibitor of IDH1-R132H, e.g., 2-(3-trifluoromethylphenyl)isothioazol-3(2H)-one (Fig. 2B) , whose core chemical structure is different from the mutant IDH1 selective inhibitors mentioned above. At present, how 2-(3-trifluoromethylphenyl)isothioazol-3(2H)-one selectively inhibits IDH1-R132H is currently unknown and further studies are currently undergoing to address this issue.
